Purpose of Review <p>Obesity increases the risk of multiple cardiovascular diseases. This paper reviewed the influence of sex on obesity treatment responses, emphasizing cardiovascular disease risk factor reduction and outcomes.</p> Recent Findings <p>The prevalence of obesity, defined as a BMI ≥ 30&#xa0;kg/m², in U.S. adults is 40.3%, with no significant difference between males and females. Across multiple studies of semaglutide and tirzepatide, weight loss was greater among females compared to males. Studies of sex-based responses in blood glucose and lipid levels remain limited for semaglutide and tirzepatide. A recent post-hoc analysis of the SURMOUNT-1 trial showed no sex differences in blood pressure response to tirzepatide. In the SELECT trial, semaglutide resulted in a 20% reduction in the primary endpoint of MACE, with no difference based on sex. Studies evaluating semaglutide and tirzepatide in patients with heart failure largely showed no sex differences in composite cardiovascular endpoints.</p> Summary <p>Evidence thus far from obesity trials has not shown a significant difference in cardiovascular outcomes by sex, though studies remain limited. Cardiologists are essential in identifying patients who would benefit from evidence-based obesity treatment to reduce future cardiovascular risk and improve outcomes among those with established cardiovascular disease. Future intervention trials should assess and report cardiovascular outcomes by sex, as data on this topic remains limited, especially when stratified by age, race, or co-morbidities.</p>